Is Repligen a buy?

Repligen has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

What sector is Repligen?

Pharmaceutical industry
Repligen

Type	Public company
Traded as	Nasdaq: RGEN S&P 400 Component
Industry	Pharmaceutical industry
Founded	1981
Founder	Alexander Rich Paul Schimmel

What does Repligen make?

biologic drugs
Repligen is a bioprocessing-focused life sciences company bringing expertise and innovation to our customers since 1981. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs.

Is Repligen overvalued?

PB vs Industry: RGEN is overvalued based on its PB Ratio (8.9x) compared to the US Life Sciences Tools and Services industry average (4.9x).

Who founded Repligen?

Alexander Rich
Paul Schimmel
Repligen/Founders

Repligen was founded in 1981 by two distinguished scientists who pioneered breakthrough advances in science and technology. Alexander Rich was co-Chair of the Repligen Board of Directors until 2014. He was a Professor at the Massachusetts Institute of Technology since 1958.

How many employees does Repligen have?

1162014
Repligen/Number of employees

When was Repligen founded?

1981
Repligen/Founded
Repligen was founded in 1981 by two distinguished scientists who pioneered breakthrough advances in science and technology. Alexander Rich was co-Chair of the Repligen Board of Directors until 2014.

How big is the market cap of Repligen?

Repligen market cap history and chart from 2006 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Repligen market cap as of April 03, 2020 is $5.12B.

What’s the stock price of Repligen ( RGEN )?

Repligen (RGEN) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues. Immunovant’s (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.

What kind of products does Repligen Corporation make?

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins).

What does Repligen chromatography product line do?

The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production.